RYZODEG 70/30
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RYZODEG 70/30 (RYZODEG 70/30).
RYZODEG 70/30 is a combination of insulin degludec (a long-acting basal insulin analog that forms soluble multi-hexamers upon subcutaneous injection, resulting in a depot from which insulin degludec is continuously and slowly absorbed, providing a flat and stable glucose-lowering effect) and insulin aspart (a rapid-acting insulin analog that exhibits a faster onset and shorter duration of action compared to regular human insulin, primarily due to enhanced monomeric state and rapid absorption). The overall effect is to lower blood glucose by facilitating cellular uptake of glucose and inhibiting hepatic glucose production.
| Metabolism | Insulin degludec is degraded by general protein degradation pathways; insulin aspart is metabolized by proteolytic enzymes. Both are not significantly metabolized by CYP450 enzymes. |
| Excretion | Renal: negligible; biliary/fecal: not established; primarily hepatic metabolism via receptor-mediated degradation. |
| Half-life | Terminal half-life: approximately 5–7 hours for the insulin degludec component, reflecting 24-hour duration; insulin aspart has a half-life of ~1 hour. |
| Protein binding | >99% bound primarily to albumin; insulin degludec also binds to specific insulin receptors. |
| Volume of Distribution | Vd: approximately 0.6–0.7 L/kg for total insulin; indicates distribution primarily into extracellular fluid. |
| Bioavailability | Subcutaneous: near 100% for both components after injection. |
| Onset of Action | Subcutaneous: insulin aspart component within 10–20 minutes; insulin degludec component within 30–90 minutes. |
| Duration of Action | Duration: up to 24 hours (insulin degludec); insulin aspart covers prandial glucose excursions for 3–5 hours. |
Subcutaneous injection. Individualize dose. Typical total daily dose is 0.5-1.0 units/kg/day. Administer once daily with the evening meal or with the largest meal. RYZODEG 70/30 is a fixed combination of insulin degludec (70%) and insulin aspart (30%).
| Dosage form | SOLUTION |
| Renal impairment | GFR 30-89 mL/min: No adjustment. GFR 15-29 mL/min: Reduce dose by 25-50%, monitor glucose. GFR <15 mL/min: Reduce dose by 50-75%, use caution. |
| Liver impairment | Child-Pugh Class A or B: No adjustment. Child-Pugh Class C: Reduce dose by 25-50% due to impaired gluconeogenesis. |
| Pediatric use | Not FDA-approved for pediatric patients. In clinical practice: individualize starting dose 0.5-1.0 units/kg/day subcutaneous once daily. |
| Geriatric use | Initiate at lower doses (e.g., 0.3-0.5 units/kg/day) due to increased risk of hypoglycemia. Titrate slowly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RYZODEG 70/30 (RYZODEG 70/30).
| Breastfeeding | Insulin degludec and insulin aspart are endogenous proteins and are excreted in breast milk in negligible amounts. No known adverse effects on the breastfed infant. M/P ratio not established for these insulins. |
| Teratogenic Risk | Insulin degludec/insulin aspart (70/30) does not cross the placenta and is not teratogenic. Poorly controlled diabetes during pregnancy increases fetal risks including miscarriage, major birth defects, stillbirth, and macrosomia. First trimester risks include congenital anomalies; second and third trimester risks include fetal overgrowth, polyhydramnios, and neonatal hypoglycemia. |
■ FDA Black Box Warning
WARNING: RISK OF HYPOGLYCEMIA. Insulin, including RYZODEG 70/30, can cause severe hypoglycemia, which may be life-threatening. Changes in insulin strength, manufacturer, type, or method of administration should be made cautiously and only under medical supervision. Concomitant use with thiazolidinediones (TZDs) may increase the risk of fluid retention and heart failure.
| Common Effects | Hypoglycemia low blood glucose level Auto antibody formation Headache Nasopharyngitis inflammation of the throat and nasal passages Upper respiratory tract infection |
| Serious Effects |
["Hypersensitivity to insulin degludec, insulin aspart, or any excipients","During episodes of hypoglycemia"]
| Precautions | ["Hyperglycemia or hypoglycemia with changes in insulin regimen","Hypoglycemia (most common adverse reaction)","Hypersensitivity and allergic reactions","Hypokalemia (may be caused by insulin, leading to cardiac arrhythmias)","Fluid retention and heart failure with concomitant TZD use","Medication errors (e.g., accidental mix-ups between insulin products)","Injection site reactions and lipodystrophy","Acute painful peripheral neuropathy with rapid improvement in glucose control"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood glucose levels frequently. Assess HbA1c every trimester. Perform fetal surveillance including ultrasound for growth and anatomy, and nonstress tests in third trimester. Monitor for maternal hypoglycemia, diabetic ketoacidosis, and preeclampsia. |
| Fertility Effects | Insulin degludec/insulin aspart does not directly impair fertility. Uncontrolled diabetes can reduce fertility in both males and females due to hormonal imbalances and metabolic disturbances. |